Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.71 |
| ▸ | CCR8 | P51685 | 1/20 | 0.71 |
| ▸ | NOS3 | P29474 | 1/20 | 0.63 |
| ▸ | NOS2 | P35228 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9611 | 1.00 | — | — | |
| SCHEMBL30421349 | 1.00 | — | — | |
| SCHEMBL30898550 | 0.96 | — | — | |
| Iodide SCHEMBL8148528 | 0.96 | — | — | |
| Fluoride SCHEMBL38652089 | 0.96 | — | — | |
| SCHEMBL17822110 | 0.96 | — | — | |
| Bromide SCHEMBL5437785 | 0.96 | — | — | |
| Hydrogen Sulfide SCHEMBL20214420 | 0.96 | — | — | |
| SCHEMBL184761 | 0.96 | — | — | |
| Ammonia Solution, Strong SCHEMBL18983640 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184987-A1 | Preparation of Retapamulin via its Pleuromutilin-thiol precursor | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2010-07-22 | — | — | US | claimed |
| US-20240218009-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240199680-A1 | SYNTHESIS OF FLUORINATED CYCLIC DINUCLEOTIDES | MERCK SHARP & DOHME LLC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240182511-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-06-06 | — | — | US | disclosed |
| CN-114901646-B | Benzotriazine bisoxides and pharmaceutical compositions thereof | 浙江瑞臻医药有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20230287032-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | MERCK SHARP & DOHME LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230174567-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | MERCK SHARP & DOHME LLC (US) | 2023-06-08 | — | — | US | disclosed |
| CN-110935489-A | Supported transition metal catalyst system through hydrogen bond action and preparation method thereof | 东华大学 | 2020-03-31 | — | — | CN | disclosed |
| EP-3129392-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT | VIIV Healthcare UK(No.4) Limited (GB) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015157483-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-15 | — | — | WO | disclosed |
| US-6232313-B1 | TREATING STROKE OR EPILEPTIC CONVULSIONS ASSOCIATED WITH EXCESSIVE CALCIUM INFLUX IN THE BRAIN CAUSED BY EXCITATORY AMINO ACIDS | ZENECA LIMITED (GB) | 2001-05-15 | — | — | US | disclosed |
| US-6214826-B1 | NERVOUS SYSTEM DISORDERS | ZENECA LIMITED (GB) | 2001-04-10 | — | — | US | disclosed |
| EP-0724583-B1 | PYRIDAZINO QUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-12-13 | — | — | EP | disclosed |
| EP-1004582-A2 | Pyridazino quinoline compounds | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| US-5744471-A | NERVOUS SYSTEM DISORDERS | ZENECA LIMITED (GB) | 1998-04-28 | — | — | US | disclosed |
| EP-0790996-A1 | PYRIDAZINOQUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| EP-0724583-A1 | PYRIDAZINO QUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1996-08-07 | — | — | EP | disclosed |
| WO-1996015127-A1 | PYRIDAZINOQUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| US-5464600-A | From phosphorous trichloride and sulfur | BAYER CORPORATION (US) | 1995-11-07 | — | — | US | disclosed |
| WO-1995011244-A1 | PYRIDAZINO QUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1995-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218009-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | STING1, IFNAR1, CGAS | CCR1 3128/4885CCR8 2445/4885NOS3 1606/4885 |
| US-20230287032-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | NUDT1, NT5C3B, DUT | CCR1 4776/4885CCR8 4487/4885NOS3 1653/4885 |
| US-20240199680-A1 | SYNTHESIS OF FLUORINATED CYCLIC DINUCLEOTIDES | NT5C3B, DUT, NT5C2 | CCR1 3005/4885CCR8 1368/4885NOS3 3735/4885 |
| US-20240182511-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | STING1, IFNAR1, CGAS | CCR1 2510/4885CCR8 1581/4885NOS3 1731/4885 |
| US-20230174567-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | NUDT1, NT5C3B, MTAP | CCR1 4190/4885CCR8 3833/4885NOS3 1617/4885 |
| US-20100184987-A1 | Preparation of Retapamulin via its Pleuromutilin-thiol precursor | PLEC, TTR, NRP1 | CCR1 3908/4885CCR8 3431/4885NOS3 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.